LYELL IMMUNOPHARMA INC (LYEL)
US55083R1041 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.65M 37.24% | 84.68M 695.12% | 130K -99.85% | 22.44K -82.74% | -100.00% | ||
| EBITDA YoY % growth | -200.85M 3.27% | -169.04M 15.84% | -226.758M -34.14% | -197.476M 12.91% | -237.896M -20.47% | -312.523M -31.37% | |
| EBIT YoY % growth | -214.47M -1.19% | -187.06M 12.78% | -247.008M -32.05% | -217.884M 11.79% | -247.887M -13.77% | -299.686M -20.90% | |
| Operating Margin | -2,013.80% | -220.90% | -190,006.15% | -970,963.64% | N/A | N/A | |
| EPS YoY % growth | N/A | -0.75 45.67% | -0.78 -4.00% | -0.80 -2.00% | -0.86 -7.69% | -0.77 10.71% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 6.50% | -0.19 19.25% | -0.20 -10.50% | -0.22 -29.00% | -0.23 -25.46% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | -43.717M -11.36% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -57.123M 4.01% | -57.11M -2.76% | -59.66M -15.78% | -64.377M -27.47% | -62.2M -8.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.17 | -0.20 | 0.03 | 16.67% |
| Q2 2024 Q2Q % growth | -0.18 | -0.21 | 0.03 | 13.92% |
| Q1 2024 Q2Q % growth | -0.24 -4.35% | -0.21 | -0.03 | -12.04% |
| Q4 2023 Q2Q % growth | -0.20 -400.00% | -0.23 | 0.03 | 14.00% |
| Q3 2023 Q2Q % growth | -0.17 39.29% | -0.26 | 0.08 | 33.33% |
| Q2 2023 Q2Q % growth | -0.18 -20.00% | -0.28 | 0.10 | 35.44% |
| Q1 2023 Q2Q % growth | -0.23 17.86% | -0.29 | 0.06 | 20.41% |
| Q4 2022 Q2Q % growth | -0.04 88.57% | -0.31 | 0.27 | 87.07% |
| Q3 2022 Q2Q % growth | -0.28 -40.00% | -0.32 | 0.04 | 11.45% |
| Q2 2022 Q2Q % growth | -0.15 83.15% | -0.32 | 0.17 | 52.56% |
| Q1 2022 Q2Q % growth | -0.28 | -0.29 | 0.01 | 4.24% |
| Q4 2021 Q2Q % growth | -0.35 | -0.28 | -0.07 | -24.78% |
| Q3 2021 Q2Q % growth | -0.20 | -0.28 | 0.08 | 27.38% |
| Q2 2021 Q2Q % growth | -0.89 | -0.37 | -0.52 | -139.05% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 34K 36.00% | 34K | % | |
| Q2 2024 Q2Q % growth | 13K -51.85% | 13K | % | |
| Q1 2024 Q2Q % growth | 3K -95.38% | 3K | % | |
| Q4 2023 Q2Q % growth | 13K -99.97% | 13K | % | |
| Q2 2023 Q2Q % growth | 27K -99.92% | 27K | % | |
| Q1 2023 Q2Q % growth | 65K -88.18% | 65K | % | |
| Q4 2022 Q2Q % growth | 48.39M 1,615.96% | 1.904M | 46.486M | 2,441.49% |
| Q3 2022 Q2Q % growth | -100.00% | 1.836M | -1.836M | -100.00% |
| Q2 2022 Q2Q % growth | 35.74M 1,258.94% | 1.088M | 34.652M | 3,184.93% |
| Q1 2022 Q2Q % growth | 550K -77.55% | 1.02M | -470K | -46.08% |
| Q4 2021 Q2Q % growth | 2.82M 22.08% | 2.907M | -87K | -2.99% |
| Q3 2021 Q2Q % growth | 2.76M 157.94% | 2.346M | 414K | 17.65% |
| Q2 2021 Q2Q % growth | 2.63M -15.71% | 2.295M | 335K | 14.60% |
| Q1 2021 Q2Q % growth | 2.45M 94.44% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 14.06% | 0% | 6.59% |
| Revenue | N/A | N/A | 0% | 175% |